You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Integrated Biotherapeutics, Inc. Topic: NIAID
Filoviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: MITOSCIENCES, INC Topic: NIGMS
DESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC Topic: NIAID
DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: TOMEGAVAX, INC. Topic: NIAID
DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: VIRION SYSTEMS, INC. Topic: NIAID
DESCRIPTION (provided by applicant): Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is associated with substantial morbidity. The impact of genital herpes as a public health threat is amplified because of its epidemiologic synergy with HIV. Epidemiological studies consistently demonstrate that HSV infection increases the risk of HIV transmission and acqu ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: TConneX Inc. Topic: DHP16C001
Thegoal is to develop asoftwaretool that implementsa novelapproach applicableto fitgeneral pharmacologic, toxicology, or other biomedical data, that mayexhibita non-monotonic dose-responserelationship for which thecurrent parametricmodels fail. Thesoftwareexplores dose-responserelationships using both monotonicand non-monotonicmodels,and estimates theassociated doseresponsecurves,which can further ...STTR Phase II 2019 Department of DefenseDefense Health Agency
SBC: BIOMIMETIX JV LLC Topic: 102
Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: KLEIN BUENDEL, INC. Topic: NCI
DESCRIPTION (provided by applicant): Over the past decade, an investigation of how family members talk through cancer on the telephone has resulted in the recent publication of a lengthy volume entitled A Natural History of Family Cancer: Interactional Resources for Managing Illness (NH). Based on the conversations analyzed for this volume, and related research on the psychosocial impacts and con ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDS
DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: INVENUX, LLC Topic: NCCAM
DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health